A $195 million plant expansion to strengthen domestic API production. Part of the company’s plan to invest $10 billion in the U.S.

An expansion of the India-based company's existing Fall River facility. Will include an 83,000-square-foot addition to increase the company’s production capacity and operational efficiency.

Construction of a plant that will produce chlorhexidine gluconate, which is primarily used as an antiseptic and surgical disinfectant.

Pledge focus is a new drug substance manufacturing campus in Virginia and expansions of R&D and cell therapy manufacturing elsewhere. 

AstraZeneca will also upgrade its U.S. clinical trial supply network and accelerate development of novel medicines.

Total investment is expected to add tens of thousands of U.S. jobs.

With a manufacturing expansion and modernization in the Research Triangle, Biogen looks to enhance its capabilities for gene-targeted therapies – expanding antisense oligonucleotide production and adding new multi-platform fill-finish capacity at both clinical and commercial scales. Advanced automation and AI-driven process controls are part of the upgrades.

Headquarters expansion that will quadruple the company's production capacity. Includes a new plant

Capability expansion for generic medicine manufacturing and R&D.

Germany-based company to build a 60,500-square-foot manufacturing facility dedicated to producing critical injection-molded components for medical devices and pharmaceutical packaging, as well as desiccant solutions

Announced plans to build a new biologics manufacturing facility as part of long-term growth strategy. The project is expected to have about a $5 billion economic impact, creating about 300 permanent high-skill jobs and over 500 construction jobs.

New research and manufacturing facility, supporting vertical integration of Ratio's current and future pipeline of next-generation radiopharmaceuticals.